SIGLEC1 and breast cancer: IL15 is important for T and NK cell activity (58) a mechanisms that our CD169+ Mo-M did not have in vitro, and for antitumor immunity (59) which does not support our prognostic data regarding CD169+ TAMs in primary breast cancers (9, 22).